AK 104 - Akesobio Australia

Drug Profile

AK 104 - Akesobio Australia

Alternative Names: AK104

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akesobio Australia
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 20 Aug 2017 Preclinical trials in Solid tumours (Late-stage disease) in Australia (IV) before August 2017 (NCT03261011)
  • 20 Aug 2017 Akesobio Australia plans a phase I trial for Solid tumours (Late-stage disease, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) (IV) in Australia (NCT03261011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top